Introduction
============

*Candida albicans* is an opportunistic fungal microorganism which resides in the gastro-intestinal tract in healthy persons ([@B16]). However, in some individuals colonization may lead to invasion and clinical disease: 75% of all woman experience vulvovaginal candidiasis at least once in there lifetime, and up to 5% of woman suffer from recurrent vulvovaginal candidiasis ([@B56]). Furthermore, when the immune system is weakened, as in immunocompromised hosts ([@B61]), *Candida* species can cause severe skin-, mucosal- and even systemic infections. In this respect, *Candida* is the fourth most common etiologic agent of sepsis in US hospitals, with 9.0% of all nosocomial blood stream infections being caused by *Candida* species. Despite current treatment strategies, the crude mortality rate associated with candidiasis remains very high at 39.2% (47.1% in intensive care unit patients and 27.0% in patients from other wards). For some *Candida* species (*C. krusei*) the crude mortality rate even reaches 58.7% ([@B62]).

While the current knowledge of the host defense against *C. albicans*, mostly derived from classical immunological studies, has recently been reviewed ([@B42]), and the pathogenesis, diagnosis and treatment of invasive candidiasis has been recently described by [@B31], in the present review we will discuss the novel approaches to understand pathophysiology of *Candida* infections that make use of the novel *omics* technologies.

Rationale
=========

Despite current treatment regimens, systems fungal infections are still associated with high morbidity and mortality. In order to develop novel treatment strategies it is crucial to gain more insight into the host response against these infections. In the past, antifungal host defense research was based on hypothesis-driven *in vitro* or experimental studies. Although these "classical" studies can validate the importance of certain aspects of antifungal defense, they have a slow progress toward providing novel insights, and they are often poor indicators of the relative importance of certain pathways, both of which are crucial when looking for novel therapy targets. In this review we will focus on systems biology research that has been performed on the (human) host defense against fungal infections. Many studies have been performed on the *omics* of the fungal pathogen itself, but these lie beyond the scope of this review (see other reviews: e.g., [@B20]).

Genomics
--------

Relatively much research has been performed on the genetic susceptibility to *Candida* diseases. A recent review summarizes these findings; many of the genetic variants contributing to *Candida* susceptibility are located in pathogen recognition- or cytokine receptors and downstream signaling molecules ([@B55]). Recently, [@B32] published the first GWAS on a fungal infection. The authors analyzed 118,989 single-nucleotide polymorphisms (SNPs) across 186 loci known to be associated with immune-mediated diseases in a cohort of 217 systemic candidemia patients and 11,920 controls. There was a significant association between candidemia and SNPs in *CD 58* (*OR* = 4.68), *LCE4A* (LCE 4A; *OR* = 4.25) and *TAGAP* (*OR* = 2.96) loci. The combination of two or more risk alleles even gave an increased risk for candidemia of 19.4-fold compared to no risk allele ([@B32]). CD58, and adhesion molecule on antigen presenting cells, appeared to be involved in the inhibition of *Candida* germination. TAGAP on the other hand was needed for optimal *Candida*-induced TNF-α production, as shown by experiments performed in *Tagap^-/-^* mice.

Transcriptomics
---------------

[@B1] published a study on the transcriptional response of THP-1 cells after 3 h of stimulation with live *C. albicans* SC5314. *TNFA, IL8, CD83, MIP1A*, and *MIP1B* were among the genes up-regulated for at least twofold, whereas *CCR2* and *NCF2* were down-regulated. A novel finding was the up-regulation of *RGS1, RGS2, RGS16, down syndrome critical region 1, CXCL2, early growth response 3, FLT4*, and *TNF-α-induced protein 6*, as these genes were not previously known to be responsive to *C. albicans* ([@B56]; [@B1]). In 2008, the authors published a similar study on vascular endothelial cells, which responded quite differently on *Candida* stimulation; genes in chemotaxis, angiogenesis and inhibition of apoptosis were mostly up-regulated in endothelial cells ([@B61]; [@B2]). Also in human umbilical vein endothelial cell lines *C. albicans* induced differential expression of genes involved in apoptosis and cell death ([@B62]; [@B40]; [@B34]). Apparently the cell type under investigation has great influence on the resulting transcriptional profile after *Candida* stimulation; In human epithelial cells stimulation with *C. albicans* causes an up-regulation of genes from the NF-κB, mitogen-activated protein kinase and phosphoinositide 3 kinase/protein kinase B immune signaling pathways ([@B39]; [@B42]), and of chemokines and adhesion molecules ([@B22]; [@B31]). On the other hand, in human granulocytes (neutrophils) *C. albicans* induces transcription of genes involved in cell-cell signaling, cell signal transduction and cell growth ([@B13]; [@B20]).

In contrast, some stimuli induce such a strong effect that this can be observed in multiple species and cell types. In the murine macrophage cell line J774.2, *C. parapsilosis* induces transcription of genes from stress-, inflammation-, chemokine-, and cytokine pathways. The highest differential expression was seen with the *TNFRSF9* gene, which was 39-fold increased after 8 h of stimulation. Also in peritoneal macrophages from Bagg albino/c mice and in human PBMC-derived macrophages *TNFRSF9* was strongly up-regulated after *C. parapsilosis* stimulation ([@B32]; [@B41]).

Transcriptomic studies on the pathogen side can also throw a light upon the reaction of the host immune system to the fungus. In order to do this, [@B12] exposed *C. albicans* to different blood fractions. *C. albicans* thrives in the absence of neutrophils. In contrast, in the presence of neutrophils *C. albicans* increases responses to overcome nitrogen- and carbohydrate starvation and genes involved in the oxidative stress response are upregulated. These results suggest that neutrophils play an essential role in the defense against *C. albicans* ([@B12]).

Transcriptomics cannot only be used to learn new things about the host immune response, it might also be used as a diagnostic tool; in a murine infection model candidemia could accurately be classified and distinguished from *Staphylococcus aureus* infection with a sensitivity and specificity of 98 and 96%, respectively. Furthermore, by looking at the transcription profile, also infection progression could be accurately predicted; day one after infection there is increased expression of *CXCL2, CXCL13*, and *IL10R*; day two after infection there is increased expression of genes in the TNF-NF*κB*-B-cell lymphoma 2 pathway; whereas at day three and four, there is down-regulation of apoptotic genes but up-regulation of genes in Toll-like receptor pathways, inflammatory cytokines, of genes involved in NF*κB*-dependent and mitogen-activated protein kinase-dependent signaling cascades, and of genes involved in T cell activation ([@B63]). Also in human blood, the transcriptional profile after bacterial stimulation (*S. aureus* and *Escherichia coli*) could be distinguished from that after fungal stimulation (*C. albicans* and *Aspergillus fumigatus*) using random forest classification ([@B8]). This information might be useful in sepsis, where early knowledge on the nature of the causative agent is crucial for selecting the appropriate anti-microbial therapy.

Another transcriptome study indicating the possibility to use transcriptomics as discovery tool was published in 2013. *Candida* infection could be discriminated from bacterial infection based on a 101-transcript feature set from *in vitro* experiments with human PBMC. Interestingly, in this set of 101 genes, genes from the type I interferon pathway were significantly overrepresented. This was unexpected as type I interferons had previously been associated with viral and bacterial infections. However, these findings were validated on a functional level in humans ([@B54]), and also in independent mice studies ([@B36]; [@B6]). In a separate transcriptome experiment in humans, *IFIH1*, also part of the type I interferon signaling pathway, was implicated in the host defense against *C. albicans* hyphae. This finding was also validated on a functional level; patients with CMC express lower levels of *IFIH1*, there is a strong correlation between genetic variation in *IFIH1* and candidemia, and cells from *IFIH1* knock out mice and PBMC with different *IFIH1* genotypes have altered cytokine production upon *C. albicans* stimulation ([@B24]).

[@B58] studied the transcriptional profile of *C. albicans* and mouse dendritic cells simultaneously. Mouse Ptx3 can bind to the *C. albicans* cell wall, and thereby regulates the transcription of fungal *Hap3* target genes, this again alters the immune response to *C. albicans*, through altered expression of mouse Mta2 target genes like *IL-2* and *IL-4* ([@B58]). [@B51] described a network inference tool (NetGenerator), which constructs gene regulatory networks from time series gene expression data. They re-analyzed the Tierney dataset, taking into account variances in replicated measurement data. Again, the inter-species interactions between *Ptx3*, *Hap3*, and *Mta2* were considered robust ([@B51]). These studies emphasize the need to take into account the fact that there is an interaction between the host and pathogen.

Proteomics
----------

Although studies using transcriptomics are a very insightful tool, they are not able to mirror fully the landscape of active molecules inside an organism; therefore systemic assessment of proteins is an important step for understanding fungal-immune interaction. Since the introduction of proteomics, this can be done in a systematic manner. When the murine macrophage RAW 264.7 cell line was exposed to live *C. albicans* SC5314, the regulation of several proteins was affected; annexin I, LyGDI, Hspa5, tropomyosin 5, and L-plastin were increased while eukaryotic translation initiation factor 3 subunit 5, Hsp 60, Hspa9a, glucose-regulated protein 58, and Hspa8a were decreased. This indicates that several processes are affected including cytoskeletal organization, oxidative responses and protein biosynthesis and refolding ([@B37]). In contrast, when murine macrophages are stimulated with heat-killed *C. albicans* the overall response is more anti-inflammatory, although there are some similarities with live *C. albicans* stimulation as well ([@B38]).

Upon separately analyzing cytosol, organelle/membrane and nucleus enriched fractions from *C. albicans*-stimulated RAW 264.7 macrophages, 17 new differentially expressed proteins were identified. These proteins are involved in pro-inflammatory and oxidative responses, immune response, unfolded protein response and apoptosis ([@B48]). Also the amount of the membrane receptor Galactin-3, a lectin receptor that recognizes b-mannans ([@B27]), was increased upon *C. albicans* stimulation, especially in phagocytic cups ([@B48]). This receptor had previously been implicated in the pathophysiology of infection by a transcriptome study in mouse macrophages infected with *C. albicans*, where a 3.4-fold up-regulation of galectin-3 was observed ([@B52]).

The first proteomics study in human cells stimulated with *Candida* was published in 2014. The differences in proteomes between human M1 and M2 macrophages were studied upon stimulation with *C. albicans*. The biggest differences were found in cytoskeletal rearrangement and metabolic routes; fructose-1,6-biphosphatase 1, a glycogenesis enzyme, is up-regulated in M1 macrophages. Interestingly, stimulation with *C. albicans* has been suggested to induce a polarization switch from M1 to M2, although one could argue that there is no full correlation between cellular markers and the function of the cell. This switch could be interpreted either as an attempt of the host to reduce damage caused by inflammation, or it could be a *Candida* pathogenicity mechanism by decreasing the immune response ([@B47]).

Proteomics can also be applied to the *in vivo* situation; in human cervical-vaginal fluids almost half of the proteins are plasma components. The presence of Alb, transferrin, immunoglobulins, apolipoproteins, alpha-1-acid glycoprotein 1 and calgranulins is positively correlated with the amount of polymorphonuclear leukocytes, but there is no difference in the protein maps of asymptomatic women and women experiencing vulvovaginal candidiasis ([@B57]). In contrast, in non-neutropenic patients, invasive candidiasis could be predicted by measuring their serum antibody signature against the *C. albicans* proteins Hsp90 and Eno1 prospectively ([@B46]).

Proteomics can be used to investigate specific proteins. Dectin-1 is an important C-type lectin receptor in the recognition of *C. albicans*, which recognizes β-1,3- and β-1,6-glucans. In order to investigate early Dectin-1 signaling, the interactome of the intracellular receptor tail was explored using a pull-down proteomics approach in mouse CD11c^+^ cells. The SHIP-1 colocalizes with Dectin-1 during zymosan phagocytosis, and relocates to *C. albicans*-containing phagosomes. Further experiments with SHIP-1 deficient granulocyte-macrophage colony-stimulating factor-derived bone marrow cells demonstrated an important role for SHIP-1 in the regulation of reactive oxygen species production ([@B3]).

Metabolomics
------------

Metabolome studies in individuals with *Candida* infections are scarce. There is one study in which the urine metabolic profile was compared between a preterm neonate with *C. parapsilosis* infection and 13 preterm controls. *N*-glycine, [D]{.smallcaps}-serine, [L]{.smallcaps}-threonine, [D]{.smallcaps}-glucose, and maltose levels are higher in urine during *C. parapsilosis* infection, whereas citric acid, hexadecanoic acid and octadecanoic acid are decreased. Interestingly, therapy efficacy can be evaluated based on the metabolic profile ([@B7]).

Microbiome
----------

Several studies suggest that the microbiome composition has an important impact on health status ([@B45]). The microbiome composition can be influenced by diet. In a mice study, dietary coconut oil reduced *C. albicans* colonization of the gastro-intestinal tract ([@B17]). *Candida* colonization is also influenced by quantitative and qualitative aspects of the microbiome. [@B28] described that *Lactobacilli* inhibit fungal adhesion and growth by producing H~2~O~2~ and bacteriocin-like compounds. Also short-chain fatty acids from *Lactobacilli* can inhibit fungal growth ([@B43]). Furthermore, *Pseudomonas aeruginosa* and *Enterococcus faecalis* can inhibit *C. albicans* hyphae formation ([@B18]). Also in a *Caenorhabditis elegans* model, *E. faecalis* inhibits *C. albicans* hyphal morphogenesis ([@B5]). On the other hand, *C. albicans* can coaggregate with *Streptococci*, which may facilitate the colonization of oral surfaces by the yeast ([@B26]).

Not only can the microbiome composition influence the extent of *Candida* colonization, it can also influence the immune response against *Candida* species ([@B30]; [@B44]; [@B50]). Mice treated with the short-chain fatty acid propionate, which also increases after the consumption of dietary fermentable fibers, have enhanced generation of macrophage and dendritic cell precursors, more dendritic cells in the lungs and reduced Th2 effector function. This demonstrates that changes in diet and metabolism can alter the immunological environment in the lungs ([@B59]).

Also in humans the microbiome composition has been demonstrated to influence the immune response against *C. albicans;* in patients with hyper IgE syndrome and CMC, there are reduced numbers of regular skin microbiome members (e.g., *Corynebacteria*), but more Gram-negative bacteria (e.g., *Acinetobacter*), of which the latter in *in vitro* stimulation experiments with PBMC suppress the *S. aureus* and *C. albicans*-induced cytokine production ([@B53]). The vaginal microbiome of patients with vulvovaginal candidiasis is highly variable, and could not be described by any single profile ([@B35]).

How the microbiome influences the immune system is not completely clear yet. One mechanism proposed by [@B64] is that *lactobacilli* in the gut can use tryptophan as their energy source and produce indole-3-aldehyde in the process. Indole-3-aldehyde stimulates the aryl hydrocarbon receptor, which induces IL-22 production in NKprotein46^+^NK1.1^low^ cells, that are in turn protective against *Candida* colonization at mucosal surfaces ([@B64]).

Mycobiome
---------

Not only antifungal immunity is affected by microbiome composition; also fungal colonization can be influenced by the host microbiome. The fungal microbiome, also known as mycobiome, is a relatively novel research area. In terms of abundance fungi are relatively rare on human skin ([@B11]). However, when the normal balance is disturbed, e.g., in immunocompromised hosts, resident fungi can expand ([@B21]). Indeed, antibiotic treatment in mice causes an altered gut microbiome that coincides with outgrowth of commensal *Candida* species in the gut ([@B29]). Also genetic factors contribute to mycobiome composition; in dectin-1 deficient mice there is an altered gut mycobiome, which subsequently increases the susceptibility to experimental colitis ([@B23]).

Oral microbiome analysis revealed that *C. albicans* was the most common fungal microorganism in healthy controls and HIV-infected participants. *Candida* colonization is negatively correlated with *Pichia* abundance. *Pichia* conditioned medium inhibits *Candida* growth and biofilms. Interestingly, in a murine oral candidiasis model *Pichia* conditioned medium lowers infection score, fungal burden, and tongue epithelial damage. This study demonstrates that findings from mycobiome data can lead to novel interesting antifungals ([@B65]).

Computational Systems Biology
-----------------------------

Technical advances in the last years have increased the availability of '*omics*' data, thereby augmenting the demands for mathematical modeling. As mentioned before, it is important to consider there is an ongoing interaction between cells, proteins and metabolites of pathogens and the host, which influences the outcome of infection. [@B9] recently gave an overview of host defense strategies and the corresponding fungal evasion mechanisms, and the computational systems biology approaches to investigate these interactions. [@B10] also reviewed the available literature on the computational analysis of PHI networks, and in addition the use of web-based databases and text-mining tools in order to optimize use of currently existing data. Last year, PHI networks for *C. albicans* and *A. fumigatus* were constructed, based on protein orthology and gene function. These networks predicted Eno1, phospholipase B, Hsp70, pyruvate kinase (CDC19) as *Candida* virulence factors, which interact with the host factors CD4, Alb and amyloid beta (A4) precursor protein, Toll-like receptor 2, and epidermal growth factor receptor, respectively. These networks can serve as a framework in the analysis of host-pathogen transcriptome and proteome data ([@B49]). It is also possible to incorporate the migration of interacting immune and *Candida* cells in three-dimensional space in a PHI network ([@B33]). Building a more detailed and accurate PHI model may aid timely stratification of sepsis patients based on their inflammatory status in the future.

Discussion
==========

Several studies have demonstrated that *Candida* infection can be discriminated from bacterial infection based on the induced transcriptome profile ([@B63]; [@B54]), suggesting that in the future transcriptomics might be used in diagnostics. However, these results should be replicated first in independent studies. This will be challenging because it is difficult to recruit large cohorts of candidemia patients. Furthermore, transcriptome studies are fairly costly and time-consuming, while rapid diagnostics are desirable. Moreover, analysis of transcriptome data is not straightforward and should be standardized between the studies ([@B25]). Still, functional genomics studies are very useful, because they can lead to the discovery of novel therapy options. Microbiome studies have indicated several (products of) microorganisms that can inhibit *Candida* growth, like *Pichia* ([@B65]), *Lactobacilli* ([@B28]; [@B43]; [@B64]), *P. aeruginosa* and *E. faecalis* ([@B18]). More research is necessary to utilize this knowledge in the development of novel treatment options.

There are some things to take into consideration when conducting or analyzing functional genomics studies. First of all, many studies do not demonstrate sample size calculations, and cohorts are usually small, introducing the possibility of false-positive findings and over-fitting of data to the specific cohort under investigation. Therefore, validation is an import issue. Many findings have not been validated in independent cohorts, making it difficult to assess their value. Of course, for *in vivo* studies it is difficult to gather large cohorts of patients, as invasive *Candida* infections are relatively scarce, especially from an individual medical center point of view. In the urine metabolome study there was one premature baby (32 weeks gestational age) with a fungal chest infection, who was compared to 13 premature healthy babies (mean gestational age 34.6). With only one patient it is difficult to discern the true effect on the metabolome of fungal infection from other (external) factors like in this case respiratory distress and gestational age ([@B7]).

Next to adequate samples size and validation in independent cohorts it is also important to keep in mind the functional validation of novel findings. Employing systems biology will always lead to a top list of genes, proteins, metabolites, or microorganisms associated with a certain phenotype like *Candida* infection. However, this does not mean that these associations are also relevant. Furthermore, it is difficult to interpret novel, unexpected findings, without knowing their functional consequence(s). Therefore results need to be validated on a functional level. For example, [@B65] demonstrated that *Candida* colonization was negatively correlated with *Pichia* abundance in HIV patients, which is a purely statistical finding. They strengthened this finding by demonstrating that *Pichia* conditioned medium inhibits *Candida* growth and biofilm formation. More importantly, *Pichia* conditioned medium ameliorated a murine oral candidiasis model ([@B65]). Furthermore, [@B32] demonstrated in a GWAS study that SNPs in *CD58*, *LCE4A*, and *TAGAP* were significantly associated with candidemia. Two of the genes were validated on a functional level; in siRNA experiments *CD58* appeared to be involved in the inhibition of *Candida* germination. *Tagap^-/-^* mice had reduced *Candida*-induced TNF-α production ([@B32]).

There is no golden standard in systems biology approaches. The correlation between different systems biology approaches is not 100%; in mice it has been reported that for only about half of the genes tested there was a correlation between transcripts and proteins, with an average correlation of 0.27 ([@B14]). Compared to the proteome the metabolome is even less subject to genetic influences but more to environmental factors (**Figure [1](#F1){ref-type="fig"}**). In a study with healthy male volunteers, up to 12% of the observed variance in metabolite concentrations could be explained by genetic variation in common SNPs ([@B15]). Although the transcriptome, proteome and metabolome are less subject to genetic influences, they are often more closely related to phenotypic traits compared to genome data ([@B19]). In contrast, clinical traits, like adiposity, were more strongly correlated to transcript levels than to protein levels in a study with mice ([@B14]).

![**Overview of omics tools used in studies on the anti-*Candida* host defense.** Host genetic-, transcriptome-, proteome-, metabolome-, microbiome-, and mycobiome data have been linked to immunity/host defense. Host genetic factors play to a lesser extent a role in consecutively transcriptome, proteome, metabolome, and microbiome and mycobiome data.](fmicb-07-00154-g001){#F1}

Also the models and experimental setups that are chosen have great influence on systems biology approaches. As discussed above, *C. albicans* induces the transcription of different principal pathways in human monocyte-like cells ([@B1]), vascular endothelial cells ([@B40]; [@B2]; [@B34]), human epithelial cells ([@B22]; [@B39]) and human granulocytes (neutrophils; [@B13]). The fungal species is of importance as well, and *TNFRSF9* transcription has so far only been shown to be up-regulated after *C. parapsilosis* stimulation ([@B41]). Most studies have been performed with *C. albicans*, while other fungal species, like *C. tropicalis*, *C. glabrata*, and *C. krusei*, are also medically relevant ([@B31]). These should also be the focus of future studies. Another aspect is fungal strain and morphology; many studies use heat-killed fungi, while these are fundamentally different from live fungi. In PBMC cultures live *C. albicans* can actively suppress IL-17 production ([@B4]), and important cytokine in the anti-*Candida* host defense ([@B60]). So although using live fungal pathogens more closely resembles an *in vivo* infection, it is more difficult to delineate host defense responses from fungal influences.

In the past few years, functional genomics studies have led to interesting novel discoveries regarding the anti-*Candida* host defense (**Table [1](#T1){ref-type="table"}**), making them a valuable addition to classical immunological studies.

###### 

Research highlights from functional genomics studies on the host immune response against *Candida albicans*

  Tool                            Model                                                                                              Main findings                                                                                                                                                                                                                                              Reference
  ------------------------------- -------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------
  Genomics                        GWAS with human candidemia patients                                                                SNPs in CD58, LCE4A, TAGAP increase risk for candidemia                                                                                                                                                                                                    [@B32]
  Transcriptomics                 *In vitro* studies with human monocyte cell line or mouse dendritic cells                          Differential expression of specific genes: RGS1, RGS2, RGS16, *down syndrome critical region 1*, CXCL2, *early growth response 3, FLT4*, *TNF-α-induced protein 6, Ptx3*, and *Mta2*                                                                       [@B1]; [@B58]; [@B51]
                                  Endothelial cells stimulated with *C. albicans*                                                    Differential regulation of certain pathways: Type I interferons; chemotaxis, angiogenesis, apoptosis, cell death, NF-κB- MAPK- and PI3K/Akt signaling; cell--cell signaling, cell signal transduction and cell growth, chemokines and adhesion molecules   [@B62]; [@B13]; [@B40]; [@B2]; [@B34]; [@B20]; [@B22]; [@B54]; [@B39]; [@B31]; [@B42]
                                  Murine candidemia model, *in vitro* studies with human blood                                       Transcriptomics can be used as a diagnostic tool to discriminate fungal from bacterial infection                                                                                                                                                           [@B63]; [@B8]
  Proteomics                      Serum from non-neutropenic patients                                                                Proteomics can be useful in prognosis: the serum antibody signature against the *C. albicans* proteins Hsp90 and Eno1 is predictive of invasive candidiasis                                                                                                [@B46]
                                  *In vitro* studies with human and murine macrophages                                               Differential regulation of certain processes: cytoskeletal organization, oxidative responses, protein biosynthesis and refolding, pro-inflammatory responses, immune response, unfolded protein response and apoptosis and metabolism                      [@B37]; [@B48], [@B47]; [@B3]
  Metabolomics                    Urine metabolome in *C. parapsilosis* neonate                                                      Increased levels of *N*-glycine, [D]{.smallcaps}-serine, [L]{.smallcaps}-threonine, [D]{.smallcaps}-glucose and maltose levels. Decreased levels of citric acid, hexadecanoic acid and octadecanoic acid                                                   [@B7]
  Microbiome                      *In vitro* experiments                                                                             Microbiome composition can influence *Candida* colonization                                                                                                                                                                                                [@B18]; [@B43]
                                  Microbiome studies in patients with skin/mucosal *C. albicans* infections, mice studies            Microbiome composition influences the host immune response against *C. albicans*                                                                                                                                                                           [@B64]; [@B53]; [@B59]
  Mycobiome                       Oral microbiome analysis in HIV patients, *in vitro* studies and a murine oral candidiasis model   *Pichia* inhibits *C. albicans*                                                                                                                                                                                                                            [@B65]
  Computational systems biology   Construction of PHI network                                                                        The host factors CD4, Alb and amyloid beta (A4) precursor protein, Toll-like receptor 2, epidermal growth factor receptor are predicted to interact with *C. albicans* virulence factors                                                                   [@B49]
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:   albumin
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:   chronic mucocutaneous candidiasis

CXCL

:   chemokine (C-X-C motif) ligand

Eno

:   enolase
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:   genome wide association study

Hap
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Hsp
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SNP

:   single nucleotide polymorphism
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:   tumor necrosis factor
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